IMRN

Immuron

IMRN

Market cap $12.9M

Overview Fund Activity

1.93 USD

+0.02

1.05%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.83

-0.10

5.18%

1 day

1.05%

5 days

4.89%

1 month

12.87%

3 months

10.29%

6 months

5.46%

Year to date

8.43%

1 year

-28.25%

5 years

-75.54%

10 years

-76.91%

About: Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Employees: 7

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

271% more capital invested

Capital invested by funds: $10.8K [Q1] → $40.1K (+$29.3K) [Q2]

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

67% more funds holding

Funds holding: 3 [Q1] → 5 (+2) [Q2]

0.39% more ownership

Funds ownership: 0% [Q1] → 0.39% (+0.39%) [Q2]

See Fund Rankings

Financial journalist opinion

Immuron partners with InvestorHub

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.

Immuron partners with InvestorHub

Immuron - FY25 global sales exceed projection, up 49% on prior year

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Flavio Palumbo, Chief Commercial Officer, said, “Immuron has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on last year.

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron Letter to Shareholders: Projects Update

Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan® clinical study in October 2025 Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025 Launch plans underway for ProIBS® in Australia Immuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 MELBOURNE, Australia, May 30, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders with a brief update on progress with a number of projects. Sales As announced on April 10, Immuron achieved record sales up to the end of March for the current Financial Year.

Immuron Letter to Shareholders: Projects Update

Immuron Travelan® highest sales in history

Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior year March 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior year March 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Flavio Palumbo, Chief Commercial Officer said, “For the first time, Immuron has exceeded A$5 million in sales - our highest fiscal year sales ever!

Immuron Travelan® highest sales in history

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron's product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron Travelan® continued strong sales growth

Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp December 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcp December 2024 Half Year AUD$1.1 million up 130% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Flavio Palumbo, Chief Commercial Officer said, “We are achieving strong growth in both Australia and North America reflecting the core ranging we secured in another nine pharmacy banner groups in Australia, distribution in ten pharmacy/grocery retailers in Canada and sales growth on amazon.com in the US.

Immuron Travelan® continued strong sales growth

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce a new research collaboration agreement with Monash University. The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens.

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Immuron Announces Travelan® Clinical Trial Update

Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses Travelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food and Drug Administration (FDA) for the recently completed Phase 2 study and will soon request an end of Phase 2 meeting which is a pre-cursor to proceeding to Phase 3. Travelan® (IMM-124E) Phase 2 Clinical Study NCT05933525: A Randomized, Double-blind, Placebo-controlled Trial Assessing the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model for Enterotoxigenic Escherichia Coli (ETEC) Immunology Statistically significant lower levels of IgA and IgG were observed for the subjects who received Travelan® compared to those who received the placebo, which may also reflect levels of exposure to ETEC antigen.

Immuron Announces Travelan® Clinical Trial Update

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time).

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time).

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

See News Rankings

Charts implemented using Lightweight Charts™